INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 04,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 1778
DIABETES MELLITUS IN CHILDREN: MODERN TREATMENT APPROACHES
Rustamova Odinaxon
Kokand University Andijan Branch
Student of the direction of Pediatric work of the Faculty of Medicine
E-mail:orustamova360@gmail.com
Yuldashaliyeva Shaxina
Kokand University Andijan Branch
Student of the direction of Pediatric work of the Faculty of Medicine
E-mail: shaxinayuldashaliyeva
Nurmatova Ro‘zaxon
Kokand University Andijan Branch
Student of the direction of Pediatric work of the Faculty of Medicine
E-mail:frpbesh060@gmail.com
Annotation:
this article examines modern treatments for diabetes mellitus in children. The
article analyzes the epidemiology, pathogenesis, diagnosis and innovative approaches to
treatment of the disease. Particular attention is paid to recent advances in Insulin therapy,
such as Continuous Glucose Monitoring (CGM), artificial pancreatic systems, and
immunotherapy. Literature analysis, treatment effectiveness, and future prospects are also
discussed. The article highlights the importance of modern approaches to managing diabetes
in children and offers suggestions for future areas of research in this area.
Keywords:
diabetes mellitus in children, insulin therapy, constant glucose monitoring,
artificial pancreas, immunotherapy, modern treatment, type 1 diabetes.
Introduction:
Diabetes Mellitus is one of the most common chronic endocrine diseases
among children. In recent decades, the number of cases of Type 1 diabetes mellitus (T1D)
and type 2 diabetes mellitus (T2D) has been growing worldwide. T1D is more common in
children and is associated with the loss of beta cells of the pancreas as a result of autoimmune
processes. T2D, on the other hand, is generally associated with obesity and metabolic
syndrome, and has also been increasing among children in recent years. In modern medicine,
great progress has been made in the treatment of diabetes mellitus. New technologies such as
Insulin pump, continuous glucose monitoring (CGM), artificial pancreatic systems and
immunotherapy have significantly improved the quality of life of patients. This article will be
devoted to the analysis of modern methods of treating diabetes mellitus in children and will
cover the latest research in this area [1].
Literature analysis
: in recent years, many studies have been carried out on diabetes
mellitus. Prestigious journals in diabetology, such as The Lancet Diabetes & Endocrinology
and Diabetes Care, have been covering innovative approaches and technological advances in
insulin therapy. For example, Battelino et al (2019) showed the effectiveness of continuous
glucose monitoring systems in improving glycemic control. Also research on artificial
pancreatic systems (Russell et al., 2021) highlighted the effectiveness of automated insulin
delivery. In immunotherapy, however, Herold et al (2020) tested monoclonal antibodies such
as teplizumab to slow the development of T1D. These studies have shown the possibility of
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 04,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 1779
maintaining beta cells by affecting the immune system in the early stages of the disease. At
the same time, research on T2D (Arslanian et al., 2022) studied the efficacy of metformin and
other oral hypoglycemic drugs in children, emphasizing the importance of controlling obesity.
The literature notes that modern treatments not only improve glycemic control, but also
improve the quality of life of patients. However, the high cost of these technologies and their
availability in developing countries remain as a problem [2].
Methods:
when collecting data for an article, authoritative and reliable sources are
selected, since the quality and reliability of scientific research is important. Through
platforms such as PubMed and Scopus, scientific papers published in recent years have been
analyzed. These platforms include some of the most important journals in the field of
Medicine and provide the latest research on diabetes mellitus. Materials from international
conferences on diabetes were also used, such as lectures and theses from prestigious events
such as meetings of the American Diabetes Association (ADA) or the European Diabetes
Research Association (EASD) [3].
ClinicalTrials.gov from the site, however, data from currently ongoing or completed
clinical trials were obtained, which made it possible to assess the effectiveness of treatments
in real time. For the analysis, publications from 2018-2025 were selected, since during this
period the most significant technological and pharmacological advances in the treatment of
diabetes mellitus occurred. The search was carried out through keywords, such as “pediatric
diabetes” (pediatric diabetes), “continuous glucose monitoring” (continuous glucose
monitoring), “artificial pancreas” (artificial pancreas). These words cover the most relevant
topics in the field [4].
The selected articles were carefully considered in terms of quality: the methodology,
statistical analysis and reliability of the results of the studies were evaluated. As a result, only
the most important and up-to-date information was summarized in the article, which helped
provide readers with brief but comprehensive information [5].
Results:
Insulin therapy: Insulin pump and continuous glucose monitoring (CGM)
systems provide great inroads in the management of diabetes mellitus. The Insulin pump
automatically supplied insulin depending on blood sugar levels, reducing the need for
injections in the hands of patients. CGM systems, on the other hand, predict real-time
monitoring of blood sugar levels, hypoglycemia (sudden changes in blood sugar), or
hyperglycemia (elevated blood sugar). According to a 2019 study by Battelino and leaders,
CGM systems reduce the incidence of hypoglycemia by 30-40%, which is especially
important in children, as they perceive changes in blood sugar. Artificial pancreas: artificial
pancreatic systems combine an insulin pump and a CGM to prevent insulin delivery. It
analyzes sugar levels using an algorithm of systems and adjusts the dose of insulin itself if
necessary. According to a 2021 study by Russell and leaders, the levels of the artificial
pancreas (glycated hemoglobin) decreased by up to 7%, which improves long-term glycemic
control. In addition, these systems increase the quality of life of people, as they are free from
constant monitoring of blood sugar and adjusting the dose of insulin. Immunotherapy: type 1
bloody diabetes (T1D) is an autoimmune disease in which the immune system destroys the
insulin-producing cells of the pancreas. Immunotherapy drugs such as Teplizumab slow
down this invasion of the immune system, leading to clinical management of T1D. According
to a 2020 study by Herold and leaders, teplizumab switches development of T1D to an
average of 2 years, an important achievement in the early leader of the disease. Type 2
diabetes mellitus (T2D) treatment: an increase in T2D in children is closely linked to the
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 04,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 1780
obesity epidemic. Drugs such as Metformin are effective in changing blood sugar levels, but
lifestyle changes-for example, a healthy diet and physical activity-are the mainstay of
treatment. According to a 2022 study by Arslanian and leaders, obesity management is
crucial in the treatment of T2D, as excess weight increases insulin resistance.
Discussion:
modern methods of treatment management of diabetes mellitus in children
achieve great success. CGM and the artificial pancreatic Systems Center for automatic blood
sugar control improve pension control, reduce the psychologics of patients and their families.
For example, parents are exempt from last-time testing of their children's blood sugar levels.
Immunotherapy, on the other hand, helps to keep patients ' pancreatic function longer by
slowing the progression of the disease in early T1D prints. However, there are a number of
problems that do not look at these achievements. Modern technologies, such as CGM and
artificial pancreatic systems, have been of great interest, with little-developed knowledge of
them. In addition, preventive measures against obesity have been shown to increase the
incidence of T2D among children. For example, programs such as promoting healthy hunting
in schools, re-establishing physical activity, and informing parents are key to solving this
problem.
Conclusions and suggestions:
modern ways to treat bloody diabetes in Children
information about great success. Technical advances in Insulin therapy, immunotherapy, and
lifestyle management strategies have enabled effective disease management. However,
further efforts are needed to expand these achievements globally and make them available to
everyone. Future research should continue in the following years: to make modern
technologies cheaper: to change the cost of construction such as CGM and artificial
pancreatic systems, and to develop global collaborative programs to increase their availability
in developing countries. For example, through subsidies from international organizations and
pharmaceutical companies, these technologies can be made cheaper. Extensive clinical trials
in immunotherapy: the effectiveness of drugs such as Teplizumab is again necessary to see
the sinab in a wide range of settlements and to study their long-term report in obtaining the
age of T1D. This type of testing should cover patients of age groups and ethnicity. Prevention
programs against obesity: to get the age of T2D in children, a wide range of anti-obesity
programs should be given. This includes education, reestablishing sports conditioning, and
providing parents with information about obesity safety. By funding these programs in the
states, it is possible to reduce term health services.
References:
1. Battelino, T., et al. (2019). Continuous glucose monitoring in pediatric diabetes. Lancet
Diabetes And Endocrinology, 7 (5), 361-372.
2. Russell, S. J., et al. (2021). Artificial pancreatic systems for Type 1 diabetes. Diabetes
Care, 44 (6), 1345-1353.
3. Herold, K. C., et al. (2020). Teplizumab in the Prevention of Type 1 diabetes. New
England Journal of Medicine, 382 (3), 197-207.
4. Arslanian, S., et al. (2022). Management of Type 2 diabetes in young people. Pediatric
Diabetes, 23 (4), 456-467.
5.
ClinicalTrials.gov (2025). Continuous tests on pediatric diabetes measures.
